Suchergebnisse - "Ferro, Antonella"

PubPharm (78)

21

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

enthalten in: BMC medicine | 2019

von Dieci, M. | Bisagni, G. | Brandes, A. | +29

22

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

enthalten in: BMC medicine | 2019

von Dieci, M. | Bisagni, G. | Brandes, A. | +29

23

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

enthalten in: Gynecologic oncology | 2019

von Daniele, G. | Arenare, L. | Scambia, G. | +25

24

Treating advanced breast cancer with metronomic chemotherapy : what is known, what is new and what is the future?

enthalten in: OncoTargets and therapy | 2019

von Cazzaniga, M. | Biganzoli, L. | Cortesi, L. | +36

25

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3) : a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von De Placido, S. | Gallo, C. | De Laurentiis, M. | +128

CommentIn: Lancet Oncol. 2018 Apr;19(4):431-432. - PMID 29482984

26

Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer : everyday clinical practice in a single centre

enthalten in: Anti-cancer drugs | 2017

von Dipasquale, M. | Murgia, V. | Veccia, A. | +8

27

Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre

enthalten in: Anti-cancer drugs | 2017

von Dipasquale, M. | Murgia, V. | Veccia, A. | +8

28

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer : predictive value of DNA-PK and phosphorylated ACC

enthalten in: Oncotarget | 2016

von Perrone, F. | Baldassarre, G. | Indraccolo, S. | +27

29

In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases

enthalten in: Virchows Archiv : an international journal of pathology | 2016

von Giuliani, S. | Ciniselli, C. | Leonardi, E. | +13

30

In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases

enthalten in: Virchows Archiv | 2016

von Giuliani, S. | Ciniselli, C. | Leonardi, E. | +13